EQT offers QIAGEN shareholders a 40% premium, but can its €10.8bn diagnostics bet unlock faster growth?
EQT agrees a €10.8 billion takeover of QIAGEN at €46.50 per share. Diagnostics growth, financing and shareholder approval remain key.
Medical Devices & Diagnostics